Evaluation of an Impedance Threshold Device as a VIIP Countermeasure

Douglas Ebert¹, Brandon Macias¹, Ashot Sargsyan¹, Kathleen Garcia¹, Michael Stenger², Alan Hargens³, Smith Johnston², David Kemp⁴, and Richard Danielson⁵

¹KBRwyle Science, Technology and Engineering, Houston, TX, ²NASA Johnson Space Center, Houston, TX, ³University of California, San Diego, CA, ⁴University College London, London, UK, and ⁵Baylor College of Medicine, Houston, TX

BACKGROUND

Visual Impairment/Intracranial Pressure (VIIP) is a top human spaceflight risk for which NASA does not currently have a proven mitigation strategy. Thigh cuffs and lower body negative pressure (LBNP) devices have been or are currently being evaluated as a means to reduce VIIP signs and symptoms, but these methods alone may not provide sufficient relief of cephalic venous congestion and VIIP symptoms. Additionally, current LBNP devices are too large and cumbersome for their systematic use as a countermeasure. Therefore, a novel approach is needed that is easy to implement and provides specific relief of symptoms. This investigation will evaluate an impedance threshold device (ITD) as a VIIP countermeasure.

SPECIFIC AIMS

Using a supine and head down tilt (HDT) model, this investigation will:

- **1. Determine if an ITD can reduce venous** congestion in the head and neck
- 2. Determine if an ITD can reduce indicators of elevated intracranial pressure

METHODS

PILOT RESULTS





Figure 3: Effect of ITD breathing on IJV cross-sectional area in the supine position. A: M-mode across the IJV without ITD, B: B-mode (2D) image of the IJV without ITD, C: M-mode across the IJV with ITD, D: B-mode image of the IJV without ITD. In panels A and C ECG is the


Figure 1: ITD and face mask; military kit shown incorporates three exhalation vents for exhalation minimized back pressure and maximum subject comfort.



The ITD provides up to 7 cm H_2O (~5 mmHg) resistance to inspiratory air flow, which upon each inhalation effectively turns the thorax into a vacuum pump that lowers the intrathoracic pressure (ITP) to facilitate venous return to the heart. The ITD is FDA-approved and was developed to augment venous return to the heart and increase cardiac output in patients with hypotension and during cardiopulmonary resuscitation (CPR). While the effect of ITD on CPR survival outcomes is controversial, it's ability to lower ITP with a concomitant decrease in intracranial pressure (ICP) is well documented¹. A similar concept that creates negative ITP during exhalation (intrathoracic pressure regulator; ITPR) decreased ICP in 16 of 20 patients with elevated ICP in a hospital pilot study². ITP and central venous pressure (CVP) have been shown to decrease in microgravity^{3,4}. However ITP drops more than CVP, indicating an increased transmural CVP. This could explain the paradoxical distention of jugular veins (JV) in microgravity despite lower absolute CVP and also suggests that JV transmural pressure is not dramatically elevated. Use of an ITD may lower JV pressure enough to remove or relieve cephalic venous congestion.

The experimental approach is to use a battery of tests that are currently being used to evaluate the effects of other interventions. Healthy test subjects (n=15) will participate in two sessions, one with an ITD and one with a sham ITD (placebo). Subjects will be evaluated in the seated and supine positions as well as 6° and 15° HDT postures. Measures taken at each posture will include IJV cross sectional area, carotid artery Doppler, measures of cardiac preload, transcranial Doppler (TCD), optic nerve sheath diameter (ONSD), superior ophthalmic vein (SOV) Doppler, facial soft tissue thickness, IJV pressure (VeinPress), optical coherence tomography (OCT), cochlear and cerebral fluid pressure analysis (CCFP), otoacoustic emissions (OAE), and intraocular pressure (IOP). Blood pressure, ECG, heart rate, and transcutaneous PCO₂ and PO₂ will be monitored throughout the experiment. Blood samples will be drawn and archived for potential one carbon pathway analysis.








Figure 5: Noninvasive indication of ICP changes in response to breathing at different postures. Tympanic Membrane Displacement (TMD) values in n=2 trials each panel. A: subjects





Figure 2: Effect of ITD breathing on ITP and ICP in a porcine model (from Convertino et al.)¹

During spaceflight experiments Braslet thigh cuffs reduced cardiac preload but only reduced the internal JV (IJV) cross sectional area by 23%. The addition of modified (open-glottis) Mueller maneuvers resulted in an IJV area reduction of 48%⁵. This project will test the ITD's ability to lower ITP in each respiratory cycle, acting to: 1) reduce venous congestion in the head and neck and 2) reduce ICP based on noninvasive indicators. The expected mechanism of action for relief of venous congestion is that in microgravity (or an analog), blood is relocated toward the heart from vasculature in the head and neck. Reduction of ICP would occur as a result of reduced ITP¹.



REFERENCES

1. Convertino VA, Cooke WH and Lurie KG. Inspiratory resistance as a potential treatment for orthostatic intolerance and hemorrhagic shock. Aviat Space Environ Med 76: 319-325, 2005.

2. Kiehna EN, Huffmyer JL, Thiele RH, Scalzo DC and Nemergut EC. Use of the intrathoracic pressure regulator to lower intracranial pressure in patients with altered intracranial elastance: a pilot study. J Neurosurg 119: 756-759, 2013.

3. Videbaek R and Norsk P. Atrial distension in humans during microgravity induced by parabolic flights. J Appl Physiol (1985) 83: 1862-1866, 1997. 4. Buckey JC, Jr., Gaffney FA, Lane LD, Levine BD, Watenpaugh DE, Wright SJ, Yancy CW, Jr., Meyer DM and Blomqvist CG. Central venous pressure in space. J Appl Physiol (1985) 81: 19-25, 1996. 5. Hamilton DR, Sargsyan AE, Garcia K, Ebert DJ, Whitson PA, Feiveson AH, Alferova IV, Dulchavsky SA, Matveev VP, Bogomolov VV and Duncan

15HDT Supine+ITE 250 200 150 100 30HUT 15HDT 15HDT+ITE Supine

200

150

100

at 15° head up tilt (15HUT), Supine, 15° head down tilt (15HDT), and Supine with ITD breathing (Supine+ITD). B: subjects at 30° head up tilt (30HUT), Supine, 15° head down tilt (15HDT), and 15° head down ITD breathing (15HDT+ITD). Higher TMD values indicate displacement lower ICP.

DISCUSSION

Pilot data demonstrate substantial reductions in IJV cross sectional area and in estimated ICP as measured by CCFP. Human subject testing is planned for February 2017.

The investigation team recognizes that ITD use as a routine countermeasure during spaceflight may not be particularly comfortable in its current form and function. The purpose of the planned work is to 1) use the ITD as a tool to further understand VIIP, and 2) establish the effectiveness of this methodology before embarking on more in-depth investigations to develop and validate a countermeasure with optimized crewmember acceptability.

Once validated, the ITD would be an exceptionally easy countermeasure to deploy and test on the ISS. Dosage could be altered through 1) duration of application and 2) inspiratory resistance set point. Effects could be additionally enhanced through co-application with other countermeasures such as thigh cuffs or LBNP.

JM. Cardiac and vascular responses to thigh cuffs and respiratory maneuvers on crewmembers of the International Space Station. J Appl

Physiol (1985) 112: 454-462, 2012.



